Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.86
+0.20 (3.53%)
Mar 13, 2026, 1:21 PM EDT - Market open
Revenue by Segment
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
|---|
Development and Commercialization of Biopharmaceutical Products | 407.32M | 333.62M | 124.46M | 52.16M | 10.10M | | | | | |
Development and Commercialization of Biopharmaceutical Products Growth | 22.09% | 168.06% | 138.61% | 416.57% | 33.36% | | | | | |
| 407.32M | 333.62M | 124.46M | 52.16M | 10.10M | | | | | |
| 22.09% | 168.06% | 138.61% | 416.57% | 33.36% | | | | | |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
|---|
| 377.81M | 319.20M | 83.28M | 15.60M | - | | | | | |
| 18.36% | 283.30% | 433.82% | - | - | | | | | |
| 29.17M | 14.34M | 41.12M | 36.53M | 10.08M | | | | | |
| 103.40% | -65.12% | 12.58% | 262.23% | 49.06% | | | | | |
| 342.00K | 78.00K | 59.00K | 31.00K | 13.00K | | | | | |
| 338.46% | 32.20% | 90.32% | 138.46% | -98.39% | | | | | |
| 407.32M | 333.62M | 124.46M | 52.16M | 10.10M | | | | | |
| 22.09% | 168.06% | 138.61% | 416.57% | 33.36% | | | | | |
Source: S&P Global Market Intelligence.